6-(2-bromoacetyl)pyridine-3-carbonitrile | 928649-94-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(2-bromoacetyl)pyridine-3-carbonitrile
• 英文别名: 6-(2-Bromoacetyl)nicotinonitrile
• CAS: 928649-94-9
• 化学式: C₈H₅BrN₂O
• 分子量: 225.044
• InChiKey: HFOHOCBHHSSGTF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  53.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  6-(2-bromoacetyl)pyridine-3-carbonitrile 在 sodium ethanolate 、 三氟乙酸 作用下， 以 乙醇 、 二氯甲烷 为溶剂， 反应 7.5h， 生成 6-[2-[2-ethoxyethyl-(2-oxo-3H-1,3-benzothiazol-6-yl)amino]thiazol-4-yl]pyridine-3-carbonitrile
  参考文献：
  名称：

  Structural Determinants of the γ-8 TARP Dependent AMPA Receptor Antagonist

  摘要：

  The forebrain specific AMPA receptor antagonist, LY3130481/CERC-611, which selectively antagonizes the AMPA receptors associated with TARP gamma-8, an auxiliary subunit enriched in the forebrain, has potent antiepileptic activities without motor side effects. We designated the compounds with such activities as gamma-8 TARP dependent AMPA receptor antagonists (gamma-8 TDAAs). In this work, we further investigated the mechanisms of action using a radiolabeled gamma-8 TDAA and ternary structural modeling with mutational validations to characterize the LY3130481 binding to gamma-8. The radioligand binding to the cells heterologously expressing GluA1 and/or gamma-8 revealed that gamma-8 TDAAs binds to gamma-8 alone without AMPA receptors. Homology modeling of gamma-8, based on the crystal structures of a distant TARP homologue, murine claudin 19, in conjunction with knowledge of two gamma-8 residues previously identified as critical for the LY3130481 TARP-dependent selectivity provided the basis for a binding mode prediction. This allowed further rational mutational studies for characterization of the structural determinants in TARP gamma-8 for LY3130481 activities, both thermodynamically as well as kinetically.

  DOI：

  10.1021/acschemneuro.7b00186
• 作为产物：
  描述：

  6-乙酰基烟腈 在 pyridinium hydrobromide perbromide 作用下， 以 四氢呋喃 为溶剂， 以80%的产率得到6-(2-bromoacetyl)pyridine-3-carbonitrile
  参考文献：
  名称：

  WO2007/28083

  摘要：

  公开号：

文献信息

• [EN] IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH<br/>[FR] DÉRIVÉS IMIDAZOLE UTILES COMME INHIBITEURS DE LA FAAH
  申请人：MERCK & CO INC

  公开号：WO2009152025A1

  公开（公告）日：2009-12-17

  The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

  本发明涉及某些咪唑衍生物，其可用作脂肪酰胺水解酶（FAAH）的抑制剂。该发明还涉及包含这些化合物作为活性成分的药物配方，以及这些化合物及其配方在治疗某些疾病中的使用，包括骨关节炎、类风湿性关节炎、糖尿病性神经病、带状疱疹后神经痛、骨骼肌肉疼痛和纤维肌痛，以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。
• [EN] 5-(7H-PYRROLO[2,3-d]PYRIMIDIN-4-YL)-5-AZASPIRO[2.5]OCTANE-8-CARBOXYLIC ACID DERIVATIVES AS NOVEL JAK KINASE INHIBITORS<br/>[FR] DÉRIVÉS D'ACIDE 5-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-5-AZASPIRO[2,5] OCTANE-8-CARBOXYLIQUE EN TANT QUE NOUVEAUX INHIBITEURS DE KINASE JAK
  申请人：LEO PHARMA AS

  公开号：WO2018141842A1

  公开（公告）日：2018-08-09

  The present invention relates to a compound according to formula (I), wherein X represents NH or O; n is an integer selected from 1-3; Y represents a bond, -C(O)O-*, -C(O)OR3-* or –C(O)NHR3-*; W is selected from the group consisting of phenyl, pyridyl, (C3-C7)cycloalkyl and 4-6 membered heterocycloalkyl; or pharmaceutically acceptable salts, hydrates, or solvates thereof. The invention relates further to said compounds for use in therapy, to pharmaceutical compositions comprising said compounds, to methods of treating diseases, with said compounds, and to the use of said compounds in the manufacture of medicaments.

  本发明涉及一种符合式(I)的化合物，其中X代表NH或O；n是从1到3选择的整数；Y代表键，-C(O)O- *，-C(O)OR3- *或-C(O)NHR3- *；W选自苯基，吡啶基，(C3-C7)环烷基和4-6成员杂环烷基的组；或其药学上可接受的盐，水合物或溶剂合物。本发明进一步涉及所述化合物在治疗中的用途，包括含有所述化合物的药物组合物，用所述化合物治疗疾病的方法，以及所述化合物用于制造药品的用途。
• 6-Arylalkylamino-2,3,4,5-Tetrahydro-1H-Benzo[D]Azepines as 5-Ht2c Receptor Agonists
  申请人：Briner Karin

  公开号：US20080269196A1

  公开（公告）日：2008-10-30

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.

  本发明提供了式（I）的6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环化合物，作为选择性5-HT2c受体激动剂，用于治疗与5-HT2c相关的疾病，包括肥胖、强迫症/强迫性障碍、抑郁症和焦虑症，其中，R6为—NR10R11，其中R10为取代的苯基烷基或取代的吡啶基烷基，其他取代基如说明书所定义。
• 6-ARYLALKYLAMINO-2,3,4,5-TETRAHYDRO-1H-BENZO[d]AZEPINES AS 5-HT2C RECEPTOR AGONISTS
  申请人：BRINER Karin

  公开号：US20110269745A1

  公开（公告）日：2011-11-03

  The present invention provides 6-substituted 2,3,4,5-tetrahydro-1H-benzo[d]azepines of Formula (I) as selective 5-HT2c receptor agonists for the treatment of 5-HT2c associated disorders including obesity, obsessive/compulsive disorder, depression, and anxiety, where, R6 is —NR10R11, where R10 is substituted phenylalkyl or substituted pyridylalkyl and other substituents are as defined in the specification.

  本发明提供了6-取代的2,3,4,5-四氢-1H-苯并[d]氮杂环化合物，其化学式为(I)，作为选择性5-HT2c受体激动剂，用于治疗5-HT2c相关疾病，包括肥胖症、强迫症、抑郁症和焦虑症，其中，R6是—NR10R11，其中R10是取代的苯基烷基或取代的吡啶基烷基，其他取代基如规范中所定义。
• IMIDAZOLE DERIVATIVES USEFUL AS INHIBITORS OF FAAH
  申请人：Lin Linus S.

  公开号：US20110269769A1

  公开（公告）日：2011-11-03

  The present invention is directed to certain imidazole derivatives which are useful as inhibitors of Fatty Acid Amide Hydrolase (FAAH). The invention is also concerned with pharmaceutical formulations comprising these compounds as active ingredients and the use of the compounds and their formulations in the treatment of certain disorders, including osteoarthritis, rheumatoid arthritis, diabetic neuropathy, postherpetic neuralgia, skeletomuscular pain, and fibromyalgia, as well as acute pain, migraine, sleep disorder, Alzeimer Disease, and Parkinson's Disease.

  本发明涉及某些咪唑衍生物，其作为脂肪酸酰胺水解酶（FAAH）抑制剂而有用。本发明还涉及包含这些化合物作为活性成分的制药配方以及这些化合物及其配方在治疗某些疾病中的使用，包括骨关节炎、类风湿性关节炎、糖尿病神经病、带状疱疹后神经痛、骨骼肌疼痛和纤维肌痛，以及急性疼痛、偏头痛、睡眠障碍、阿尔茨海默病和帕金森病。